The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | ASH 2017: combination therapy for CLL highlights
Numerous trials worldwide are now focusing on combination therapy for relapsed/refractory chronic lymphocytic leukemia (CLL). In this interview, Barbara Eichhorst, MD, of the University Hospital Cologne, Cologne, Germany, discusses the take-home messages from data for combination therapy for CLL presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
